6533b7d7fe1ef96bd126871c
RESEARCH PRODUCT
Clinical benefit of vedolizumab on articular manifestations in patients with active spondyloarthritis associated with inflammatory bowel disease.
Mario CottoneFabio Salvatore MacalusoFrancesco CicciaSara RennaAmbrogio OrlandoAroldo RizzoR. Orlandosubject
Genetics and Molecular Biology (all)medicine.medical_specialtyExacerbationT CellImmunologyPremisesAntibodies Monoclonal HumanizedBiochemistryInflammatory bowel diseaseGastroenterologyGeneral Biochemistry Genetics and Molecular BiologyNew onsetVedolizumab03 medical and health sciences0302 clinical medicineRheumatologyInternal medicineSpondylarthritismedicineImmunology and AllergyHumansIn patientSacroiliitis030203 arthritis & rheumatologyBiochemistry Genetics and Molecular Biology (all)business.industrymedicine.diseaseInflammatory Bowel Diseasesdigestive system diseasesRheumatologyTreatmentClinical trial030211 gastroenterology & hepatologySpondyloarthritis; T Cells; Treatment; Rheumatology; Immunology and Allergy; Immunology; Biochemistry Genetics and Molecular Biology (all)Spondyloarthritibusinessmedicine.drugdescription
Vedolizumab (VDZ) is a new biological agent which was recently approved for the treatment of inflammatory bowel disease (IBD)1 following the good clinical responses reported by clinical trials for both Crohn's disease2 and ulcerative colitis.3 However, the effects of VDZ on extraintestinal manifestations were not reported in these trials, and the ‘real life’ experience is still limited. On these premises, we read with interest the recent work by Varkas et al 4 reporting a series of five patients with IBD who were treated with VDZ and promptly developed new onset or exacerbation of spondyloarthritis (SpA), irrespective of the response to treatment on intestinal symptoms. Although the hypotheses proposed …
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2017-01-01 | Annals of the rheumatic diseases |